Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study

被引:6
作者
Mannu, Gurdeep S. [1 ,2 ]
Wang, Zhe [1 ]
Dodwell, David [1 ]
Broggio, John [3 ]
Charman, Jackie [3 ]
Darby, Sarah C. [1 ]
机构
[1] Univ Oxford, Nuffield Dept Populat Hlth, Richard Doll Bldg,Old Rd Campus, Oxford, England
[2] Univ Oxford, Nuffield Dept Surg Sci, Richard Doll Bldg,Old Rd Campus, Oxford, England
[3] NHS England, Natl Dis Registrat Serv, Birmingham, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2024年 / 384卷
关键词
RISK; DIAGNOSIS; TRIAL;
D O I
10.1136/bmj-2023-075498
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To evaluate the long term risks of invasive breast cancer and death related to breast cancer after nonscreen detected ductal carcinoma in situ. Risks for women in the general population and for women diagnosed with ductal carcinoma in situ via the screening programme were compared. DESIGN Population based cohort study. SETTING Data from the National Disease Registration Service. PARTICIPANTS All 27 543 women in England who were diagnosed with ductal carcinoma in situ, outside the NHS breast screening programme, during 1990 to 2018. MAIN OUTCOME MEASURES Incident invasive breast cancer and death caused by breast cancer. RESULTS By 31 December 2018, 3651 women with non-screen detected ductal carcinoma in situ had developed invasive breast cancer, more than four times higher than expected from national cancer incidence rates (ratio of observed to expected rate was 4.21 (95% conference interval 4.07 to 4.35)). The ratio of observed to expected rate of developing invasive breast cancer remained increased throughout follow-up among women aged <45-70 years. The 25 year cumulative risks of invasive breast cancer by age at diagnosis of ductal carcinoma in situ were 27.3% for <45 years, 25.2% for 45-49 years, 21.7% for 50-59 years, and 20.8% for 60-70 years. 908 women died of breast cancer, almost four times higher than that expected from breast cancer death rates in the general population (ratio of observed to expected rate 3.83 (3.59 to 4.09)). The ratio of observed to expected rate of mortality attributed to breast cancer remained increased throughout followup. The 25 year cumulative risks of breast cancer death by age at ductal carcinoma in situ diagnosis were 7.6% for <45 years, 5.8% for 45-49 years, 5.9% for 50-59, and 6.2% for 60-70 years. Among women aged 50-64 years, and therefore eligible for breast screening by the NHS, the ratio of observed to expected rate of invasive breast cancer in women with non-screen detected compared with screen detected ductal carcinoma in situ was 1.26 (95% conference interval 1.17 to 1.35), while the ratio for mortality from breast cancer was 1.37 (1.17 to 1.60). Among 22 753 women with unilateral ductal carcinoma in situ undergoing surgery, those who had mastectomy rather than breast conserving surgery had a lower 25 year cumulative rate of ipsilateral invasive breast cancer (mastectomy 8.2% (95% conference interval 7.0% to 9.4%), breast conserving surgery with radiotherapy 19.8% (16.2% to 23.4%), and breast conserving surgery with no radiotherapy recorded 20.6% (18.7% to 22.4%)). However, reductions did not translate into a lower 25 year cumulative rate of deaths attributable to breast cancer (mastectomy 6.5% (4.9% to 10.9%), breast conserving surgery with radiotherapy 8.6% (5.9% to 15.5%), breast conserving surgery with no radiotherapy recorded 7.8% (6.3% to 11.5%)). CONCLUSIONS For at least 25 years after their diagnosis, women with non-screen detected ductal carcinoma in situ had higher long term risks of invasive breast cancer and breast cancer death than women in the general population. Additionally, they had higher long term risks than women with screen detected ductal carcinoma in situ. Mastectomy was associated with lower risks of invasive breast cancer than breast conserving surgery, even when accompanied by radiotherapy. However, risks of breast cancer death appeared similar for mastectomy, breast conserving surgery with radiotherapy, and breast conserving surgery with no radiotherapy recorded.
引用
收藏
页数:11
相关论文
共 16 条
[1]  
[Anonymous], BREAST SCREEN PROGR
[2]   Comparison of various characteristics of women who do and do not attend for breast cancer screening [J].
Banks, E ;
Beral, V ;
Cameron, R ;
Hogg, A ;
Langley, N ;
Barnes, I ;
Bull, D ;
Reeves, G ;
English, R ;
Taylor, S ;
Elliman, J ;
Harris, CL .
BREAST CANCER RESEARCH, 2002, 4 (01) :R1
[3]   Risk of subsequent invasive breast cancer after a diagnosis of ductal carcinoma in situ (DCIS) [J].
Cheung, Shan ;
Booth, Mary E. ;
Kearins, Olive ;
Dodwell, David .
BREAST, 2014, 23 (06) :807-811
[4]  
Correa C, 2010, J NATL CANCER INST M, V2010, P162, DOI [10.1093/jncimonographs/lgq039, DOI 10.1093/JNCIMONOGRAPHS/LGQ039]
[5]   The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study aaaaaa [J].
Elshof, Lotte E. ;
Schaapveld, Michael ;
Rutgers, Emiel J. ;
Schmidt, Marjanka K. ;
de Munck, Linda ;
van Leeuwen, Flora E. ;
Wesseling, Jelle .
BREAST CANCER RESEARCH, 2017, 19
[6]   Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women [J].
Elshof, Lotte E. ;
Schaapveld, Michael ;
Schmidt, Marjanka K. ;
Rutgers, Emiel J. ;
van Leeuwen, Flora E. ;
Wesseling, Jelle .
BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (03) :553-563
[7]   Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study [J].
Elshof, Lotte E. ;
Tryfonidis, Konstantinos ;
Slaets, Leen ;
van Leeuwen-Stok, A. Elise ;
Skinner, Victoria P. ;
Dif, Nicolas ;
Pijnappel, Ruud M. ;
Bijker, Nina ;
Rutgers, Emiel J. Th. ;
Wesseling, Jelle .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (12) :1497-1510
[8]   The LORIS Trial: Addressing Overtreatment of Ductal Carcinoma In Situ [J].
Francis, A. ;
Fallowfield, L. ;
Rea, D. .
CLINICAL ONCOLOGY, 2015, 27 (01) :6-8
[9]   The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA). [J].
Kanbayashi, Chizuko ;
Thompson, Alastair Mark ;
Hwang, Eun-Sil Shelley ;
Partridge, Ann H. ;
Rea, Daniel William ;
Wesseling, Jelle ;
Shien, Tadahiko ;
Mizutani, Tomonori ;
Shibata, Taro ;
Iwata, Hiroji .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10]   Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study [J].
Mannu, Gurdeep S. ;
Wang, Zhe ;
Broggio, John ;
Charman, Jackie ;
Cheung, Shan ;
Kearins, Olive ;
Dodwell, David ;
Darby, Sarah C. .
BMJ-BRITISH MEDICAL JOURNAL, 2020, 369